Quantcast
Last updated on April 17, 2014 at 13:24 EDT

Latest treatment of multiple sclerosis Stories

2010-12-01 09:36:00

BURLINGTON, Mass., Dec. 1, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that less than 30 percent of surveyed relapsing-remitting multiple sclerosis (MS) patients in the U.S. indicate that they would request a switch to an emerging agent that matches a dosing, safety and efficacy profile similar to emerging and recently launched oral MS agents such as Merck Serono/EMD Serono's oral cladribine...

2010-11-04 05:00:00

ANN ARBOR, Mich., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing. These grants represent approximately 38% of the Company's total research...

2010-11-02 08:13:00

EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US. ChartTrends®: Multiple Sclerosis is an annual publication based on patient level data collected on 1,000 MS patients being treated with disease modifying agents (DMAs). In addition to helping to define the DMA-treated MS patient (demographics, co-morbidities, concomitant medications,...

2010-10-15 02:15:00

PARIS, October 15, 2010 /PRNewswire-FirstCall/ -- - Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate...

2010-10-12 11:36:00

PHILADELPHIA, Oct. 12 /PRNewswire/ -- MS-Leaders.org, a medical education portal from Medical Logix, LLC, is inviting neurologists and multiple sclerosis treating clinicians to participate in an exciting medical education platform designed to share best practices in the management of MS patients. MS-Leaders.org provides physicians with engaging and clinically relevant educational resources, including continuing medical education, to deliver a breadth of content to meet the needs of busy...

2010-09-22 07:30:00

SILVER SPRING, Md., Sept. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) "Gilenya is the first oral drug that can slow the progression of disability and reduce the frequency and severity of...

2010-09-22 00:30:00

EAST HANOVER, N.J., Sept. 22 /PRNewswire/ -- Today Novartis announced that the US Food and Drug Administration (FDA) approved the oral multiple sclerosis (MS) treatment Gilenya(TM) (fingolimod) 0.5 mg daily, a first-line treatment for relapsing forms of multiple sclerosis - the most common forms of the disease. The FDA approval makes Gilenya the first oral treatment indicated for relapsing forms of MS available in the US. To view the multimedia assets associated with this release,...

2010-07-15 07:00:00

WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists have low awareness of Novartis/Mitsubishi Tanabe's FTY-720 (Gilenia) among the surveyed oral emerging therapies for the treatment of multiple sclerosis (MS). According to the new report, Brand Perception Series: Physician Segmentation in Multiple Sclerosis, just over one-third of surveyed physicians...

2010-06-28 09:17:00

Study shows ITMTX may have beneficial role in progressive forms of MS NEW YORK, June 28 /PRNewswire-USNewswire/ -- The Multiple Sclerosis Research Center of New York (MSRCNY), together with the International Multiple Sclerosis Management Practice (IMSMP), today announced that results from its Intrathecal Methotrexate Treatment in Multiple Sclerosis study have been published in this month's issue of Journal of Neurology. This study reports on the feasibility of using intrathecal...

2010-06-15 07:00:00

WALTHAM, Mass., June 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the multiple sclerosis drug market, Novartis/Mitsubishi Tanabe Pharma's oral disease-modifying therapy Gilenia (fingolimod/FTY-720) remains on track to achieve blockbuster status by 2018, following a recent positive recommendation by a U.S. Food and Drug Administration (FDA) panel regarding Gilenia's safety and efficacy...